MCID: NVS001
MIFTS: 48

Neovascular Glaucoma

Categories: Eye diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Neovascular Glaucoma

MalaCards integrated aliases for Neovascular Glaucoma:

Name: Neovascular Glaucoma 12 60 15 17
Glaucoma, Neovascular 45 74
Secondary Angle-Closure Glaucoma with Rubeosis 12
Glaucoma Neovascular 56

Characteristics:

Orphanet epidemiological data:

60
neovascular glaucoma
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

Disease Ontology 12 DOID:1687
MeSH 45 D015355
MESH via Orphanet 46 D015355
UMLS via Orphanet 75 C0017609
Orphanet 60 ORPHA94058
UMLS 74 C0017609

Summaries for Neovascular Glaucoma

MalaCards based summary : Neovascular Glaucoma, also known as glaucoma, neovascular, is related to microvascular complications of diabetes 5 and coats disease. An important gene associated with Neovascular Glaucoma is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are MAPK signaling pathway and Endochondral Ossification. The drugs Triamcinolone and Ranibizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotypes are glaucoma and visual loss

Related Diseases for Neovascular Glaucoma

Diseases related to Neovascular Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 5 30.7 PGF VEGFA
2 coats disease 30.5 RS1 VEGFA
3 retinal detachment 30.3 RS1 VEGFA
4 microvascular complications of diabetes 1 30.3 TGFB2 VEGFA
5 arteries, anomalies of 30.0 PGF VEGFA
6 glaucoma, primary open angle 29.7 SLC6A13 TGFB2
7 retinoschisis 1, x-linked, juvenile 11.5
8 retinal vein occlusion 10.4
9 melanoma 10.4
10 central retinal vein occlusion 10.4
11 microvascular complications of diabetes 2 10.4
12 rubeosis iridis 10.4
13 cataract 10.2
14 branch retinal artery occlusion 10.2
15 retinal artery occlusion 10.2
16 diabetes mellitus 10.2
17 preretinal fibrosis 10.2 TGFB2 VEGFA
18 vitreous disease 10.2 TGFB2 VEGFA
19 macular holes 10.2 TGFB2 VEGFA
20 kuhnt-junius degeneration 10.2 PGF VEGFA
21 epithelioid hemangioendothelioma 10.2 PGF VEGFA
22 cancer-associated retinopathy 10.2 PGF VEGFA
23 melanoma, uveal 10.2
24 neurofibromatosis, type iv, of riccardi 10.2
25 central retinal artery occlusion 10.2
26 ischemia 10.2
27 retinal vascular occlusion 10.2 PGF VEGFA
28 limb ischemia 10.1 PGF VEGFA
29 ectopic pregnancy 10.1 PGF VEGFA
30 placental insufficiency 10.1 PGF VEGFA
31 neurofibromatosis, type i 10.1
32 uveitis 10.1
33 carotid artery disease 10.1
34 retinal vascular disease 10.1 PGF VEGFA
35 severe pre-eclampsia 10.1 PGF VEGFA
36 corneal disease 10.1 TGFB2 VEGFA
37 retinal ischemia 10.0
38 neuroretinitis 10.0
39 open-angle glaucoma 10.0
40 retinal vasculitis 10.0
41 sympathetic ophthalmia 10.0
42 optic nerve glioma 10.0
43 carotid artery occlusion 10.0
44 vasculitis 10.0
45 glioma 10.0
46 juvenile retinoschisis 10.0
47 lens disease 9.9 PEX19 VEGFA
48 breast cancer 9.9
49 multiple sclerosis 9.9
50 retinoblastoma 9.9

Graphical network of the top 20 diseases related to Neovascular Glaucoma:



Diseases related to Neovascular Glaucoma

Symptoms & Phenotypes for Neovascular Glaucoma

Human phenotypes related to Neovascular Glaucoma:

60 33 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glaucoma 60 33 obligate (100%) Obligate (100%) HP:0000501
2 visual loss 60 33 hallmark (90%) Very frequent (99-80%) HP:0000572
3 retinal vein occlusion 60 33 hallmark (90%) Very frequent (99-80%) HP:0012636
4 iris neovascularization 60 33 hallmark (90%) Very frequent (99-80%) HP:0011497
5 photophobia 60 33 frequent (33%) Frequent (79-30%) HP:0000613
6 ocular pain 60 33 frequent (33%) Frequent (79-30%) HP:0200026
7 visual acuity test abnormality 60 33 frequent (33%) Frequent (79-30%) HP:0030532
8 abnormality of the optic nerve 60 33 frequent (33%) Frequent (79-30%) HP:0000587
9 abnormality of central retinal artery 60 33 frequent (33%) Frequent (79-30%) HP:3000032
10 ocular hypertension 33 frequent (33%) HP:0007906
11 retinal vascular proliferation 60 33 occasional (7.5%) Occasional (29-5%) HP:0007850
12 corneal stromal edema 60 33 occasional (7.5%) Occasional (29-5%) HP:0012040
13 abnormal anterior chamber morphology 33 occasional (7.5%) HP:0000593
14 retinal detachment 60 33 very rare (1%) Very rare (<4-1%) HP:0000541
15 abnormality of the anterior chamber 60 Occasional (29-5%)
16 increased intraocular pressure 60 Frequent (79-30%)
17 abnormality of the posterior segment of the globe 60 Occasional (29-5%)
18 abnormality of the uvea 60 Frequent (79-30%)

Drugs & Therapeutics for Neovascular Glaucoma

Drugs for Neovascular Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
2
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
3
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
4 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
5 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
6 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
7 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
8 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
10 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
11 Immunologic Factors Phase 4,Phase 2,Phase 3,Not Applicable
12 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
13 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Mitogens Phase 4,Phase 3,Phase 2,Phase 1
15 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Endothelial Growth Factors Phase 4,Phase 3,Phase 1,Phase 2
19 Mitomycins Phase 4,Phase 3,Phase 2,Not Applicable
20 Alkylating Agents Phase 3,Phase 2
21 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2
23 Antibiotics, Antitubercular Phase 3,Phase 2
24 Pharmaceutical Solutions Phase 2, Phase 3,Phase 1
25 insulin Phase 2, Phase 3
26 Insulin, Globin Zinc Phase 2, Phase 3
27 Anesthetics Phase 2
28 Antibodies Phase 1
29 Antibodies, Monoclonal Phase 1
30 Immunoglobulins Phase 1
31
Racepinephrine Approved Not Applicable 329-65-7 838
32
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
33
Formaldehyde Approved, Vet_approved 50-00-0 712
34
Pilocarpine Approved, Investigational Not Applicable 54-71-7, 92-13-7 5910
35
Emodepside Investigational, Vet_approved Not Applicable 155030-63-0
36 Epinephryl borate Not Applicable
37 Anti-Infective Agents
38 Disinfectants
39 Peripheral Nervous System Agents Not Applicable
40 Autonomic Agents Not Applicable
41 Muscarinic Agonists Not Applicable
42 Neurotransmitter Agents Not Applicable
43 Cholinergic Agents Not Applicable

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
2 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
3 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
4 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
5 Intraocular Bevacizumab (Avastin) for Rubeosis Iridis Completed NCT00557232 Phase 4 bevacizumab
6 Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
7 Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Unknown status NCT02914626 Phase 3 Intravitreal ranibizumab
8 Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma. Unknown status NCT01314170 Phase 3
9 Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma Unknown status NCT01128699 Phase 3 Subconjunctival Avastin
10 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied Completed NCT03639675 Phase 3 Aflibercept (EYLEA, BAY86-5321);Topical IOP-lowering drugs
11 Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients Completed NCT02396316 Phase 3 Aflibercept (Eylea, BAY 86-5321);Sham Injection
12 Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis Completed NCT02641457 Phase 3 Aflibercept;Ranibizumab
13 Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion Completed NCT02033031 Phase 3 Lucentis intravitreal injection;Avastin intravitreal injection
14 Bevacizumab for Central Retinal Vein Occlusion Study Completed NCT00906685 Phase 3 bevacizumab;Sham bevacizumab injection
15 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3 ranibizumab
16 Oculusgen (Ologen) Glaucoma MMC Control in Estonia Completed NCT00524758 Phase 3 MMC in Trabeculectomy
17 Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Completed NCT00853905 Phase 2, Phase 3 Triesence;balanced salt solution BSS
18 Anti-VEGF Treatment for Prevention of PDR/DME Active, not recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
19 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
20 Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Not yet recruiting NCT02947867 Phase 2, Phase 3 aganirsen
21 A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy Withdrawn NCT01589718 Phase 3 Macugen;Sham
22 Analysis of Aqueous and Vitreous Humor Unknown status NCT02067013 Phase 2 Ranibizumab
23 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Unknown status NCT03006081 Phase 2 Intravitreal Aflibercept injection
24 Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment. Unknown status NCT02957760 Phase 2 Hydroxycarbamid
25 Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Completed NCT01051583 Phase 2
26 Ahmed Glaucoma Valve Surgery With Mitomycin-C Active, not recruiting NCT02805257 Phase 2 Mitomycin-C
27 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Active, not recruiting NCT02222610 Phase 2 0.5 mg ranibizumab
28 Lucentis for New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
29 Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion Completed NCT00406471 Phase 1 Ranibizumab (Lucentis)
30 A Pilot Study for the Treatment of Iris Neovascularization With Macugen Completed NCT00295828 Phase 1
31 Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Completed NCT00765921 Phase 1 ranibizumab
32 Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma Unknown status NCT02260219 Not Applicable
33 Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection Unknown status NCT00491712 Not Applicable
34 Triamcinolone for Ahmed Glaucoma Valve Unknown status NCT02653963 Not Applicable Adjunctival Triamcinolone
35 Prevalence of Glaucoma in the Israeli Arab Population Unknown status NCT01546740
36 Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135 Not Applicable 0.5mg intraocular Ranibizumab (Lucentis)
37 The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Completed NCT03154892 Not Applicable
38 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed NCT01711879 Not Applicable Aflibercept
39 Intravitreal Bevacizumab for Neovascular Glaucoma Completed NCT00384631 Not Applicable Avastin
40 Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy Completed NCT01758757 Not Applicable
41 Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy Completed NCT01425112 Not Applicable
42 Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion Completed NCT02645747 Aflibercept (Eylea, BAY86-5321)
43 CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases Completed NCT03940664
44 Compliance to Ophthalmic Follow-up Examinations and Surgical Outcome for Proliferative Diabetic Retinopathy Completed NCT01307072
45 the Pops-titration Versus the Slow-coagulation Cyclophotocoagulation in Treatment of Refractory Glaucoma Completed NCT01774227 Not Applicable
46 Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT Recruiting NCT03648814 Not Applicable
47 Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Recruiting NCT02874040 Not Applicable
48 The Effect of the Glycemic Variability on Macular Retinal Microcirculation and Cognitive Functions in Patient With Type 1 Diabetes Recruiting NCT03821753
49 Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study Recruiting NCT02865473 Not Applicable Pilocarpine
50 Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma Active, not recruiting NCT03187418 Not Applicable

Search NIH Clinical Center for Neovascular Glaucoma

Cochrane evidence based reviews: glaucoma, neovascular

Genetic Tests for Neovascular Glaucoma

Anatomical Context for Neovascular Glaucoma

MalaCards organs/tissues related to Neovascular Glaucoma:

42
Eye, Endothelial, Testes, Retina, Myeloid, B Cells, Placenta

Publications for Neovascular Glaucoma

Articles related to Neovascular Glaucoma:

(show top 50) (show all 458)
# Title Authors Year
1
Herpes Zoster Ophthalmicus, Central Retinal Artery Occlusion, and Neovascular Glaucoma in an Immunocompetent Individual. ( 30820294 )
2019
2
Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. ( 30862502 )
2019
3
Uncontrolled neovascular glaucoma - an alarming manifestation of chronic myeloid leukemia on imatinib therapy - a case report and review of literature. ( 30672497 )
2019
4
Ahmed glaucoma valve implantation versus suprachoroidal silicone tube implantation following the injection of bevacizumab into the anterior chamber in patients with neovascular glaucoma. ( 30610423 )
2019
5
Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis. ( 30726529 )
2019
6
Preservation of retinoblastoma group E eyes with neovascular glaucoma using intravenous chemotherapy: risk factors and outcomes. ( 30796055 )
2019
7
Expression of platelet-derived growth factor-C in aqueous humor of patients with neovascular glaucoma and its correlation with vascular endothelial growth factor. ( 30803266 )
2019
8
Efficacy and safety of Ex-PRESS® mini shunt surgery versus trabeculectomy for neovascular glaucoma: a retrospective comparative study. ( 30866871 )
2019
9
Neovascular glaucoma regulation by arylsulfonyl indoline-benzamide (ASIB) through targeting NF-kB signalling pathway. ( 31093481 )
2019
10
Choroidal hypoperfusion: an indicator of low tension neovascular glaucoma. ( 29256166 )
2019
11
Prediction of Surgical Outcome After Trabeculectomy for Neovascular Glaucoma With Anterior Segment Optical Coherence Tomography: A Methodological Issues. ( 30531190 )
2019
12
RAPIDLY PROGRESSIVE NEOVASCULAR GLAUCOMA FROM CYTOMEGALOVIRUS RETINITIS IN A NON-HUMAN IMMUNODEFICIENCY VIRUS PATIENT. ( 29533389 )
2018
13
Systemic diffuse large B-cell lymphoma masquerading as neovascular glaucoma. ( 29380792 )
2018
14
Baerveldt or Ahmed glaucoma valve implantation with pars plana tube insertion in Japanese eyes with neovascular glaucoma: 1-year outcomes. ( 30568422 )
2018
15
Randomized comparative trial of diode laser transscleral cyclophotocoagulation versus Ahmed glaucoma valve for neovascular glaucoma in Chinese - a pilot study. ( 30573944 )
2018
16
Long-Term Outcome of Intravitreal Bevacizumab Followed by Ahmed Valve Implantation in the Management of Neovascular Glaucoma. ( 28992424 )
2018
17
Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy. ( 29116399 )
2018
18
Rapidly progressive neovascular glaucoma following coronary artery bypass graft surgery in a patient with type 1 diabetes mellitus: a case report. ( 29429414 )
2018
19
Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma. ( 29468218 )
2018
20
Iris Thickness and Severity of Neovascular Glaucoma Determined Using Swept-Source Anterior-segment Optical Coherence Tomography. ( 29485476 )
2018
21
Comparison of polypropylene and silicone Ahmed® glaucoma valves in the treatment of neovascular glaucoma: A 2-year follow-up. ( 29521039 )
2018
22
Puerarin regulates neovascular glaucoma through pigment epithelium‑derived growth factor‑induced NF‑κB signaling pathway. ( 29620183 )
2018
23
Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis. ( 29620670 )
2018
24
Clinical Efficacy and Safety of the EX-PRESS Filtration Device in Patients with Advanced Neovascular Glaucoma and Proliferative Diabetic Retinopathy. ( 29643784 )
2018
25
An atypical case of neurosarcoidosis presenting with neovascular glaucoma. ( 29671151 )
2018
26
Topical Corticosteroid-Resolved Rubeosis Iridis with Neovascular Glaucoma Caused by Noninfectious Granulomatous Uveitis. ( 29681844 )
2018
27
Comparison of the safety and efficacy of triple sequential therapy and transscleral cyclophotocoagulation for neovascular glaucoma in the angle-closure stage. ( 29728640 )
2018
28
Assessing the role of ranibizumab in improving the outcome of glaucoma filtering surgery and neovascular glaucoma. ( 29781319 )
2018
29
Pars plana insertion of glaucoma shunt in eyes with refractory neovascular glaucoma: Case report. ( 29879052 )
2018
30
Left acute neovascular glaucoma after right carotid endarterectomy. ( 29942895 )
2018
31
Neovascular glaucoma: Handling in the future. ( 30038883 )
2018
32
A Case of Refractory Neovascular Glaucoma Treated With a XEN 45 Implant. ( 30059408 )
2018
33
Safety of antivascular endothelial growth factor administration in the ocular anterior segment in pterygium and neovascular glaucoma treatment: Systematic review and meta-analysis. ( 30142821 )
2018
34
Prediction of Surgical Outcome After Trabeculectomy for Neovascular Glaucoma With Anterior-segment Optical Coherence Tomography. ( 30188465 )
2018
35
High interleukin-8 level in aqueous humor is associated with poor prognosis in eyes with open angle glaucoma and neovascular glaucoma. ( 30266980 )
2018
36
A Case Report of Intravitreal Bevacizumab for Iris Metastasis of Small Cell Lung Carcinoma with Neovascular Glaucoma. ( 30283326 )
2018
37
Iris Morphological Features in Patients with 360° Angle-Closure Neovascular Glaucoma: An Anterior Segment Optical Coherence Tomography Study. ( 30483110 )
2018
38
Risk factors for neovascular glaucoma after vitrectomy in eyes with proliferative diabetic retinopathy. ( 30532517 )
2018
39
Central retinal artery occlusion without underlying chronic ocular ischemic syndrome may lead to neovascular glaucoma. ( 29055729 )
2017
40
A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial. ( 28302155 )
2017
41
Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy. ( 28272234 )
2017
42
The efficacy of Alahmady ring implantation in the management of neovascular glaucoma. ( 28356708 )
2017
43
Efficacy and safety of intravitreal ranibizumab with panretinal photocoagulation followed by trabeculectomy compared with Ahmed glaucoma valve implantation in neovascular glaucoma. ( 28393031 )
2017
44
Ahmed Valves vs Trabeculectomy Combined with Pans Plana Vitrectomy for Neovascular Glaucoma with Vitreous Hemorrhage. ( 28430329 )
2017
45
Circumpapillary retinal nerve fiber layer thickness, anterior lamina cribrosa depth, and lamina cribrosa thickness in neovascular glaucoma secondary to proliferative diabetic retinopathy: a cross-sectional study. ( 28446148 )
2017
46
Management of neovascular glaucoma with intravitreal ranibizumab, panretinal photocoagulation, and subsequent 5-fluorouracil augmented trabeculectomy: A case report. ( 28640115 )
2017
47
Clinical Features of Ocular Ischemic Syndrome and Risk Factors for Neovascular Glaucoma. ( 28682017 )
2017
48
Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages. ( 28713590 )
2017
49
Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors. ( 28721444 )
2017
50
Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience. ( 28848323 )
2017

Variations for Neovascular Glaucoma

Expression for Neovascular Glaucoma

Search GEO for disease gene expression data for Neovascular Glaucoma.

Pathways for Neovascular Glaucoma

Pathways related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.17 PGF TGFB2 VEGFA
2 11.07 TGFB2 VEGFA
3 10.96 SLC6A11 SLC6A13 TGFB2
4 10.85 TGFB2 VEGFA
5
Show member pathways
10.21 SLC6A11 SLC6A13

GO Terms for Neovascular Glaucoma

Cellular components related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 TGFB2 VEGFA

Biological processes related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.73 PGF TGFB2 VEGFA
2 response to drug GO:0042493 9.69 PGF SLC6A11 TGFB2
3 angiogenesis GO:0001525 9.61 PGF TGFB2 VEGFA
4 positive regulation of endothelial cell proliferation GO:0001938 9.55 PGF VEGFA
5 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.54 PGF VEGFA
6 heart morphogenesis GO:0003007 9.52 TGFB2 VEGFA
7 cellular response to hormone stimulus GO:0032870 9.49 PGF UCP2
8 positive chemotaxis GO:0050918 9.48 PGF VEGFA
9 neurotransmitter transport GO:0006836 9.46 SLC6A11 SLC6A13
10 sprouting angiogenesis GO:0002040 9.4 PGF VEGFA
11 vascular endothelial growth factor signaling pathway GO:0038084 9.37 PGF VEGFA
12 induction of positive chemotaxis GO:0050930 9.32 PGF VEGFA
13 positive regulation of mast cell chemotaxis GO:0060754 9.26 PGF VEGFA
14 gamma-aminobutyric acid transport GO:0015812 9.16 SLC6A11 SLC6A13
15 positive regulation of cell division GO:0051781 9.13 PGF TGFB2 VEGFA
16 response to hypoxia GO:0001666 8.92 PGF TGFB2 UCP2 VEGFA

Molecular functions related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 PGF TGFB2 VEGFA
2 chemoattractant activity GO:0042056 9.26 PGF VEGFA
3 neurotransmitter binding GO:0042165 8.96 SLC6A11 SLC6A13
4 gamma-aminobutyric acid:sodium symporter activity GO:0005332 8.62 SLC6A11 SLC6A13

Sources for Neovascular Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....